Key facts
- Piton Therapeutics’s last known valuation is $65.5M (Oct 2020).
- It has raised $15.3M; the latest was Later Stage VC ($7.0M) in Dec 2024.
- Notable investors include Plum Ventures, K2VC, Future Capital Discovery Fund, Prescience Point Capital Management, ABI LAB — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Piton Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Piton Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Piton Therapeutics
Developer of precision therapeutics designed for inflammatory, neurological, and metabolic diseases. The company offers small-molecule drugs that modulate the gut microbiome's role in chronic conditions, enabling patients with disorders like Ulcerative Colitis, Type 2 Diabetes, Autism Spectrum Disorder, and Parkinson's Disease to access targeted and disease-modifying treatments.
- Sector
- Healthcare
- HQ
- Watertown, MA, United States
- Founded
- 2016
- Employees
- 12
- Website
- pitontx.com/
- Ownership
- Privately Held (backing)
Piton Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Piton Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Piton Therapeutics in its N-PORT filings yet. We sweep new filings monthly.